The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease. ・The program could ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results ...

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

As of Thursday, December 11, Atossa Therapeutics, Inc.’s ATOS share price has surged by 9.41%, which has investors questioning if this is right time to sell.

Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...

The MarketWatch News Department was not involved in the creation of this content. Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development ...